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Aims Heart failure may occur following acute myocardial infarction, but with the use of high-sensitivity cardiac troponin
assays we increasingly diagnose patients with minor myocardial injury. Whether troponin concentrations remain a
useful predictor of heart failure in patients with acute coronary syndrome is uncertain.
...................................................................................................................................................................................................
Methods
and results
We identified all consecutive patients (n= 4748) with suspected acute coronary syndrome (61 ± 16 years, 57%
male) presenting to three secondary and tertiary care hospitals. Cox-regression models were used to evaluate the
association between high-sensitivity cardiac troponin I concentration and subsequent heart failure hospitalization.
C-statistics were estimated to evaluate the predictive value of troponin for heart failure hospitalization. Over
2071 years of follow-up there were 83 heart failure hospitalizations. Patients with troponin concentrations above
the upper reference limit (URL) were more likely to be hospitalized with heart failure than patients below the URL
(118/1000 vs. 17/1000 person years, adjusted hazard ratio: 7.0). Among patients with troponin concentrations
<URL the rate of heart failure hospitalization was 2.80-fold higher [95% confidence interval (95% CI 1.81–4.31)]
per doubling of troponin concentration. On adding troponin to a model with demographic, cardiovascular risk fac-
tor, and clinical variables, the prediction of heart failure hospitalization improved considerably (C-statistic 0.80 vs.
0.86, P< 0.001).
...................................................................................................................................................................................................
Conclusion Cardiac troponin is an excellent predictor of heart failure hospitalization in patients with suspected acute coronary
syndrome. The strongest associations were observed in patients with troponin concentrations in the normal refer-
ence range, in whom high-sensitivity cardiac troponin assays identify those at increased risk of heart failure who
may benefit from further investigation and treatment.
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Introduction
Heart failure is common, important, and costly. More than 15 million
people are thought to have heart failure in Europe.1 It is estimated that
in the USA alone the total direct costs of heart failure care is more
than $20 billion per annum.2 Despite improvements in diagnosis and
the development of effective therapies for patients with heart failure,
the case-fatality rate at 5-years is 50%.3–6 One of the major causes of
heart failure is acute myocardial infarction with symptoms developing
in those patients who have sustained significant myocardial injury and
ventricular impairment.7,8 However, with the development of high-
sensitivity cardiac troponin assays we increasingly identify patients with
minor myocardial injury.9–12 Whether cardiac troponin concentration
remains a useful predictor in this group of patients is uncertain.
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Furthermore, high sensitivity cardiac troponin assays are increasingly
used to risk-stratify patients to identify those likely to benefit from hos-
pitalization and/or further investigation.13 We therefore examined the
association and predictive utility of cardiac troponin concentration for
subsequent admission to hospital with heart failure in consecutive pa-
tients with suspected acute coronary syndrome.
Methods
We included 4748 consecutive patients who presented to the Emergency
Department with suspected acute coronary syndrome to three secondary
and tertiary hospitals in Edinburgh, Scotland between 1 June 2013 and 31
January 2014 and who survived to discharge. These patients were enrolled
in the standard care arm of a stepped-wedge cluster randomized controlled
trial (ClinicalTrials.gov registration NCT01852123). All patients who had
cardiac troponin requested by the attending clinician for suspected acute
coronary syndrome were included. Patients were excluded if they had been
admitted previously during the study period or did not reside in Scotland.13
The study was performed with the approval of the National Research Ethics
Committee, and in accordance with the Declaration of Helsinki.
High-sensitivity cardiac troponin I assay
The ARCHITECTSTAT high-sensitive troponin I assay (Abbott
Laboratories, Abbott Park, IL, USA) was used to measure cardiac tropo-
nin I concentration in all patients. The limit of detection (LoD) of this
assay is 1.2 ng/L and the upper reference limit (URL) or 99% centile in
women is 16 and 34 ng/L in women and men, respectively.13 The lowest
cardiac troponin I concentration with an inter-assay coefficient of vari-
ation (CV) of less than 10% was 4.7 ng/L according to the manufacturer
and was 6 ng/L in our laboratory.14,15 In patients with more than one
measure of cardiac troponin, the highest concentration was used. Values
below the LoD were assigned a value of 1.2 ng/L (n= 506, 10.7%).
Classification of myocardial infarction
The electronic patient record system TrakCare (InterSystems
Corporation, Cambridge, MA, USA) was used to acquire baseline charac-
teristics for each patient, including cardiovascular risk factors and past
medical events.13 Hyperlipidaemia and hypertension were defined as a
documented history of the condition, or by the respective use of lipid-
lowering or anti-hypertensive medication. Smoking was defined as cur-
rent or ex-smoking at admission. Killip class was determined by the at-
tending clinician. Myocardial infarction type was classified by two
investigators (A.S., A.A.) independently using the Third Universal
Definition of Myocardial Infarction,16 with discrepancies being adjudicated
by third investigator (N.M.). Patients were classified using all available clin-
ical information at the time of the index admission (including peak tropo-
nin and serial change in troponin when these were available). Type 1
myocardial infarction was identified when myocardial necrosis occurred
in the context of a presentation with suspected acute coronary syndrome
with chest pain or evidence of myocardial ischaemia on the electrocar-
diogram. Patients with symptoms and signs of myocardial ischaemia on
the electrocardiogram that were thought to be due to increased oxygen
demand or decreased supply (e.g. tachyarrhythmia, hypotension, or an-
aemia) and myocardial necrosis were classified as having a type 2 myocar-
dial infarction. Myocardial injury was defined as evidence of myocardial
necrosis in the absence of any clinical features of myocardial ischaemia. A
detailed description of the classification criteria was published
elsewhere.13
Outcomes
Outcomes were censored on 31 March 2014 (median follow-up 156
days, interquartile range 98–218 days). Hospitalization and death during
the follow-up period were obtained via linkage to the national hospital
database (‘the Scottish Morbidity Record’, SMR01). Heart failure was
defined as any hospitalization assigned the code I50. All heart failure diag-
noses were adjudicated by a physician and cardiologist independently
(D.S., A.S.). Criteria for the adjudication of heart failure were based on re-
view of inpatient clinical records and based on symptoms of congestive
cardiac failure supported by imaging evidence of left ventricular
dysfunction.
Agreement was 100% between the two investigators. Cardiac death
was defined as deaths due to myocardial infarction, arrhythmia, or heart
failure (ICD-10 codes I21/22 and I46-50).
Statistical analysis
For all analyses, patients who died during the index admission were
excluded. Analyses were performed for cardiac troponin I concentration
as categorical and continuous variable. Patients were categorized into five
groups according to the highest measured cardiac troponin I concentra-
tion. Group 5 included all patients who had cardiac troponin concentra-
tions above the sex-specific 99th centile URL (>34 ng/L for men and
>16 ng/L for women).13,17 The remaining patients were split into quartiles
(Groups 1–4) by sex: 1.2–2.0, 2.1–4.0, 4.1–8.0, and 8.1–34.0 ng/L for men;
1.2–1.9, 2.0–2.9, 3.0–6.0, and 6.1–16.0 ng/L for women. These categories
were assigned prior to analysing associations between groups and any of
the study outcomes. For the analysis as a continuous variable, cardiac
troponin concentrations were log-transformed as a linearizing transform-
ation. Summary statistics were obtained for baseline characteristics by
category. Hazard ratios (HRs) for first subsequent hospitalization with heart
failure and for first subsequent hospitalization with heart failure or cardiac
death were estimated according to group in Cox regression models ad-
justing for age, sex, cardiovascular risk factors (diabetes mellitus, hyper-
tension, ischaemic heart disease, and previous myocardial infarction), and
clinical features (systolic blood pressure and creatinine concentration).
As there were neither heart failure hospitalizations nor cardiac deaths in
the two groups with the lowest cardiac troponin concentrations, these
two groups were collapsed. Similar models were used to estimate associ-
ations for troponin (log-transformed) as a continuous variable.
Polynomial terms and penalized splines were used to present the associ-
ations, which were non-linear, in tables and figures, respectively.
Sensitivity analyses were performed having excluded patients with
heart failure at the index presentation. Subgroup analyses of log-troponin
concentration were conducted for patients with cardiac troponin con-
centrations below and above the 99th centile URL. Patients with elevated
cardiac troponin concentrations were additionally analysed according to
the diagnosis at the index presentation: type 1 myocardial infarction, type
2 myocardial infarction, and myocardial injury. The discrimination of
troponin (with and without additional variables) was estimated using area
under the receiver operating characteristic curves (C-statistics).
Confidence intervals (CIs) for the C-statistics were obtained via boot-
strapping.18 Analyses were performed in IBM SPSS Statistics Version
22.0.0 (Armonk, NY: IBM, USA, 2014) and R Version 3.0.1 (R project for
statistical computing, Vienna, Austria).
Results
There were 4870 patients with suspected acute coronary syndrome
(mean age 61 ± 16 years, 57% men) enrolled between 1 June 2013 and
31 January 2014. One hundred and twenty-two patients died during
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..the index presentation and these patients were excluded from this ana-
lysis. The median cardiac troponin concentration was 5 ng/L (interquar-
tile range 2–22 ng/L). There were 1151 (24%) patients with cardiac
troponin concentrations above the URL (Group 5); 723 (15.2%) pa-
tients were classified as having type 1 myocardial infarction, 158 (3.3%)
type 2 myocardial infarction, and 270 (5.7%) with myocardial injury.
Patients with higher cardiac troponin concentrations were older,
had a higher Killip class, and more cardiovascular risk factors. They
were also more likely to have been treated with angiotensin convert-
ing enzyme inhibitors, angiotensin receptor blockers or beta block-
ers, and had higher creatinine concentrations (Table 1).
Heart failure hospitalization
Eighty-three patients were hospitalized with heart failure (40/1000
person years) during a total of 2071 person years follow-up. Patients
with cardiac troponin concentrations above the URL (Group 5)
were more likely to be hospitalized with heart failure than patients
with lower troponin concentrations (118/1000 person years vs.
2/1000 in Groups 1 and 2 combined, HR: 47.2, Table 2). Similar asso-
ciations were evident after adjustment for age and sex, and after fur-
ther adjustment for diabetes mellitus, hypertension, ischaemic heart
disease, previous myocardial infarction, systolic blood pressure, and
creatinine concentration (Table 2).
In all patients the association between cardiac troponin concentra-
tion and heart failure hospitalization was non-linear (P for non-linearity
<0.001), with a plateau evident at around 30 ng/L as shown via penal-
ized spline smoothing functions (Figure 1, Supplementary material on-
line, Table S2 for model coefficients).
Among patients with cardiac troponin concentrations below the
URL there was a nearly three-fold increase in risk of heart failure hos-
pitalization per doubling of troponin concentration (HR: 2.80, 95% CI
1.81–4.31), whereas among all patients with cardiac troponin con-
centration above this threshold there was no evidence of an associ-
ation between increasing cardiac troponin concentrations and heart
failure hospitalization (HR: 1.03, 95% CI 0.96–1.12, Table 2). On strat-
ifying by the adjudicated diagnosis, patients with type 1 and type 2
myocardial infarction were consistent with negative or weakly posi-
tive associations between peak cardiac troponin concentration and
hospitalization with heart failure (1.06, 95% CI 0.96–1.17 and 0.81,
95% CI 0.57–1.14, respectively). For patients with myocardial injury
there was a positive association (HR: 1.21, 95% CI 1.00–1.47),
although this was much weaker than for patients with cardiac tropo-
nin concentrations below the URL and the CI included the
.................................................................................................................................................
....................................................................................................................................................................................................................
Table 1 Baseline characteristics of patients with suspected acute coronary syndrome stratified by cardiac troponin
concentration
Patients stratified by peak troponin concentration
Group 1 Group 2 Group 3 Group 4 Group 5a
n5 900 (19%) n5899 (19%) n5 899 (19%) n5 899 (19%) n5 1151 (24%)
Troponin, ng/L (median, range)
Men 1.9 (1.2–2.0) 3.0 (2.1–4.0) 5.9 (4.1–8.0) 15.0 (8.1–34.0) 484.5 (34.1–50 000)
Women 1.2 (1.2–1.9) 2.0 (2.0–2.9) 3.0 (3.0–6.0) 9.0 (6.1–16.0) 100.0 (16.1–50 000)
Age, years (mean, SD) 49 (13) 58 (14) 66 (14) 71 (14) 71 (15)
Females 378 (42%) 378 (42%) 378 (42%) 378 (42%) 545 (47%)
Diabetes mellitus 68 (9%) 115 (15%) 130 (16%) 162 (21%) 191 (18%)
Hypertension 120 (16%) 224 (29%) 290 (36%) 316 (40%) 444 (41%)
Hyperlipidaemia 119 (16%) 209 (27%) 223 (28%) 238 (30%) 336 (31%)
Ischaemic heart disease 93 (12%) 201 (26%) 304 (38%) 372 (47%) 409 (38%)
Previous myocardial infarction 58 (6%) 120 (13%) 159 (18%) 209 (23%) 244 (21%)
Previous stroke 27 (3%) 48 (5%) 54 (6%) 90 (10%) 107 (9%)
Heart failure at index presentation 0 (0%) 7 (1%) 21 (2%) 83 (9%) 243 (21%)
Current or ex-smoker 315 (57%) 309 (58%) 287 (56%) 252 (59%) 401 (63%)
Admission ACE inhibitor/ARB 88 (16%) 160 (28%) 209 (36%) 221 (42%) 270 (38%)
Admission beta blocker 65 (12%) 108 (19%) 166 (29%) 189 (36%) 236 (33%)
Killip class
1 784 (99%) 784 (97%) 786 (96%) 699 (88%) 923 (85%)
2 8 (1%) 25 (3%) 30 (4%) 84 (11%) 108 (10%)
3 0 0 0 (0%) 14 (2%) 52 (5%)
4 0 0 0 1 (0%) 3 (0%)
Creatinine, mg/dL (mean, SD) 0.84 (0.14) 0.86 (0.21) 0.91 (0.26) 1.07 (0.63) 1.13 (0.75)
Heart rate, b.p.m. (mean, SD) 79 (18) 78 (20) 78 (20) 83 (24) 86 (29)
Systolic blood pressure, mmHg (mean, SD) 136 (21) 139 (25) 138 (23) 140 (28) 139 (30)
Values are numbers (proportion), except where indicated.
SD, standard deviation; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker.
aGroup 5—all patients with cardiac troponin concentrations >upper reference limit.
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.null (Supplementary material online, Table S1). Similar associations
were found in analyses using presentation instead of maximal car-
diac troponin concentrations (Supplementary material online,
Table S1).
Similar associations were found in women and men
(Supplementary material online, Figure S1). The HR in patients with
cardiac troponin concentrations below the URL was 3.01 (95% CI
1.50–6.03) for women and 2.68 (95% CI 1.54–4.69) for men. Among
patients with troponin concentration above the URL the HR was
1.11 (95% CI 1.01–1.21) for women and 0.88 (95% CI 0.76–1.03)
for men.
Heart failure hospitalization or cardiac
death
Similar associations were evident for the combined outcome of hos-
pitalization with heart failure or cardiac death in unadjusted analyses
and after adjusting for age and sex, and after further adjustment for
diabetes mellitus, hypertension, ischaemic heart disease, previous
myocardial infarction, systolic blood pressure, and creatinine concen-
tration (Table 2 and Figure 1).
Sensitivity analyses
Sensitivity analyses after the exclusion of 354 patients with heart fail-
ure [111 patients with troponin <99% centile URL (3.1%), 132 pa-
tients with type 1 MI (18.3%), 31 patients with type 2 MI (19.6%), and
80 patients with myocardial injury (29.6%)] identified during the index
presentation identified similar associations for cardiac troponin and
subsequent heart failure hospitalization, and the composite endpoint
of heart failure hospitalization or cardiac death (Supplementary ma-
terial online, Tables S2 and S4).
Discrimination
For heart failure hospitalization, cardiac troponin concentration alone
achieved similar discrimination to a model incorporating clinical features
(age, sex, diabetes mellitus, hypertension and ischaemic heart disease,
previous myocardial infarction, systolic blood pressure, and creatinine
concentration) (C-statistic 0.80, 95% CI 0.76–0.83 and 0.80, 95% CI
0.75–0.85, respectively, Table 3). Moreover, when troponin concentra-
tion was added to the risk factors model, the prediction improved to
0.86 (95% CI 0.82–0.89). Similar discrimination was evident for the pre-
diction of heart failure hospitalization or cardiac death (C-statistic 0.87,
95% CI 0.84–0.90). Discrimination was similar in men and women (0.86,
95% CI 0.81–0.91 and 0.87, 95% CI 0.82–0.92, respectively).
Discussion
In consecutive patients with suspected acute coronary syndrome
high-sensitivity cardiac troponin I concentrations predict an increased
risk of subsequent hospitalization with heart failure or cardiac death.
Interestingly the relationship between cardiac troponin concentra-
tion and heart failure was strongest for patients without myocardial
infarction. In these patients, the risk of subsequent hospitalization
....................................................................................................................................................................................................................
Table 2 Heart failure hospitalization or cardiac death in suspected acute coronary syndrome stratified by troponin
concentration
Group 1 Group 2 Group 3 Group 4 Group 5 All patients
n5 900 (19%) n5899 (19%) n5 899 (19%) n5 899 (19%) n5 1151 (24%) n5 4748 (100%)
Troponin (ng/L): Men 1.2–2.0 2.1–4.0 4.1–8.0 8.1–34.0 34.1–50 000 1.2–50 000
Troponin (ng/L): Women 1.2–1.9 2.0–2.9 3.0–6.0 6.1–16.0 16.1–50 000 1.2–50 000
Heart failure hospitalization
Events, n 0 2 4 21 56 83
Person years 407 410 390 390 473 2071
Incidence (per 1000 person years) 0 5 10 54 118 40
HR, unadjusted 1 4.1 21.8 47.2
HR, model 1 1 2.4 9.9 21.4
HR, model 2 1 3.0 11.7 28.9
HR, model 1, continuousa 2.80 (1.81–4.31) 1.03 (0.96–1.12)
Heart failure hospitalization or cardiac death
Events, n 0 2 5 29 84 120
Person years 407 410 390 390 473 2071
Incidence (per 1000 person years) 0 5 13 74 178 58
HR, unadjusted 1 5.2 30.2 71.3
HR, model 1 1 2.7 11.6 27.6
HR, model 2 1 2.7 14.4 34.1
HR, model 1, continuousa 3.03 (2.05–4.48) 1.03 (0.97–1.10)
Hazard ratio (95% CI). Model 1 adjusts for age and sex; model 2 additionally adjusts for diabetes mellitus, hypertension, and ischaemic heart disease, previous myocardial infarc-
tion, systolic blood pressure at the index presentation, creatinine at the index presentation and an interaction term between ischaemic heart disease and previous myocardial
infarction.
HR: hazard ratio.
aAnalysis of troponin as a continuous variable among patients with troponin levels below the upper reference limit (Groups 1–4) and above the upper reference limit (Group 5).
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Figure 1 Association between peak cardiac troponin concentration and time to first event for heart failure hospitalization, and heart failure hospi-
talization or cardiac death. Departures from linearity were explored using penalized spline smoothing functions (grey band). The association was also
analysed after stratifying patients into those with a peak troponin concentration less than the upper reference limit (URL) (red line), and those with
troponin concentrations above the URL, with a specific index diagnosis (type 1 myocardial infarction, green line; type 2 myocardial infarction, blue;
myocardial injury, purple).
....................................................................................................................................................................................................................
Table 3 Discrimination of cardiac troponin and a model based on clinical features for heart failure hospitalization or
cardiac death
Area under the curvea Troponinb Modelc Troponinb 1modelc
Heart failure hospitalization 0.80 (0.76–0.83) 0.80 (0.75–0.85) 0.86 (0.82–0.89)
Men 0.80 (0.75–0.85) 0.81 (0.74–0.88) 0.86 (0.81–0.91)
Women 0.81 (0.77–0.86) 0.80 (0.73–0.87) 0.87 (0.82–0.92)
Heart failure hospitalization or cardiac death 0.81 (0.79–0.84) 0.82 (0.78–0.86) 0.87 (0.84–0.90)
Men 0.82 (0.79–0.86) 0.84 (0.79–0.89) 0.88 (0.84–0.92)
Women 0.82 (0.79–0.86) 0.81 (0.75–0.87) 0.88 (0.84–0.92)
a95% CI in brackets.
bIncluding troponin squared.
cModel of clinical features age, sex, diabetes mellitus, hypertension, ischaemic heart disease, previous myocardial infarction, systolic blood pressure, and creatinine
concentration.
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increased three-fold for every doubling in cardiac troponin concen-
tration and the addition of troponin to a model with clinical features
and cardiovascular risk factors markedly improved discrimination.
Heart failure may occur following myocardial infarction in patients
with significant myocardial injury and left ventricular systolic impair-
ment. Our observations from a large cohort of consecutive patients
with suspected acute coronary syndrome demonstrate that any in-
crease in cardiac troponin concentration <99th centile is associated
with an increase in the risk of developing heart failure. Interestingly, in
patients with cardiac troponin concentrations >99th centile, further
increases in cardiac troponin did not identify those at higher risk. This
was true even among patients with type 1 myocardial infarction in
whom one might expect more extensive myocardial injury to be
associated with a greater risk of heart failure.19
The observation that the magnitude of cardiac troponin concentra-
tion is not associated with the risk of heart failure in patients with myo-
cardial infarction should perhaps be interpreted with caution, as it has
not previously been reported. It is possible that differences in the tim-
ing of cardiac troponin measurement could obscure a relationship be-
tween troponin concentration and heart failure. In our cohort the
majority of patients with troponin concentrations >99th centile had
measures at presentation and 12 h (71%) after the onset of symptoms
(approximately 6 h following presentation), as recommended by inter-
national guidelines for the diagnosis of myocardial infarction.16
However, it is now recognized that cardiac troponin concentrations
measured during the plateau phase (24–72 h after presentation) are
more closely related to the structural sequelae of myocardial infarction
as identified on cardiac magnetic resonance imaging, such as scarring
and left ventricular impairment, than are troponin concentrations at 6–
12 h which are obtained for diagnosis.20 An alternative explanation is
that other clinical factors are more important than peak troponin con-
centration in determining whether patients with myocardial infarction
develop heart failure, such as the timing and completeness of revascula-
rization, the extent and severity of coronary heart disease, and the
presence of comorbid conditions. Competing risks is an unlikely ex-
planation, as similar associations were evident for the composite out-
come of heart failure hospitalization or cardiac death as were observed
for heart failure hospitalization alone.
Interestingly, in those patients without myocardial infarction where
cardiac troponin concentrations were within the normal reference
range, troponin concentration was a powerful independent predictor
of heart failure hospitalization. Those patients with cardiac troponin
concentrations in the lowest two quartiles did not go on to have
heart failure or cardiac death. This provides further support to our
previous observations that patients with suspected acute coronary
syndrome and low cardiac troponin concentrations (<5 ng/L) are at
very low risk of cardiovascular events.13 It may be that some patients
with cardiac troponin concentrations between 5 ng/L and the URL
have asymptomatic structural heart disease and are at risk of subse-
quent decompensation. Echocardiography is recommended in pa-
tients with myocardial infarction, but is not routinely performed in
those in whom the diagnosis is excluded. Further studies are now
needed to determine whether those patients with cardiac troponin
concentrations within the normal reference range, but greater than
5 ng/L, would benefit from additional investigations, and treatments
to prevent heart failure events.
Indeed, the discrimination of cardiac troponin for predicting subse-
quent heart failure and cardiac death is excellent.21 When added to
clinical features and cardiovascular risk factors the area under the re-
ceiver operator characteristic score was 0.87, a level indicating that a
test is potentially useful for event prediction in individual patients.22
Importantly, discrimination was similar in men and women. Previous
authors have reported associations between high-sensitivity troponin
I/T and heart failure events in the general adult population and in pa-
tients with stable coronary artery disease.23–26 We now demonstrate
that cardiac troponin predicts heart failure admission in unselected
patients presenting with suspected acute coronary syndrome, in
whom troponin measurement is performed routinely. Our discrimin-
ation estimate needs to be validated in an external cohort, but it is
unlikely that we have overestimated the C-statistic through over fit-
ting, as only a single continuous variable (troponin) was added to the
baseline model.
A strength of this study was that it included all consecutive patients
presenting to either secondary or tertiary care hospitals, following re-
ferral or self-presentation, in whom acute coronary syndrome was
suspected, making this a truly representative sample. However, this
approach did mean that the timing of troponin sampling was at the
discretion of the attending physician and will have varied by service-
related or patient factors. Nonetheless, our findings are generalizable
as they reflect usual clinical practice and because they were similar
for maximal and presentation cardiac troponin concentrations. A se-
cond limitation of this study is that patients were censored at
10 months, and associations between cardiac troponin and heart fail-
ure hospitalization or cardiac death at later times could not be deter-
mined. However, the first 6-month period is arguably of greatest
clinical interest to physicians in preventing subsequent hospitalization.
Finally, we do not have N-terminal pro-BNP or BNP concentrations
available in this cohort, which would likely further improved the pre-
dictive power of our model for heart failure.23,27–29
Conclusion
High-sensitivity cardiac troponin I is an excellent predictor of heart
failure hospitalizations and cardiac death in patients with suspected
acute coronary syndrome. Troponin concentrations may, in particu-
lar, be used to identify patients without myocardial infarction who
are at risk of heart failure. It may be that this group of patients will
benefit from N-terminal pro-BNP testing and/or echocardiography.
Intervention studies, ideally randomized clinical trials, are needed to
determine whether the costs of such a strategy are justified by bene-
fits such as reducing or delaying heart failure admissions.
Supplementary material
Supplementary material is available at European Heart Journal – Quality
of Care and Clinical Outcomes online.
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